Lin PJ - Search Results

1

Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.

Ma S, Lavelle TA, Ollendorf DA, Lin PJ. Ma S, et al. Among authors: lin pj. Appl Health Econ Health Policy. 2022 May;20(3):395-404. doi: 10.1007/s40258-021-00711-y. Epub 2022 Jan 10. Appl Health Econ Health Policy. 2022. PMID: 35001292 Free PMC article. Review.

2

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.

Saret CJ, Winn AN, Shah G, Parsons SK, Lin PJ, Cohen JT, Neumann PJ. Saret CJ, et al. Among authors: lin pj. Blood. 2015 Mar 19;125(12):1866-9. doi: 10.1182/blood-2014-07-592832. Epub 2015 Feb 5. Blood. 2015. PMID: 25655601 Free PMC article. Review.

3

Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence.

Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ. Zhong Y, et al. Among authors: lin pj. Value Health. 2015 Mar;18(2):308-14. doi: 10.1016/j.jval.2014.12.004. Epub 2015 Feb 7. Value Health. 2015. PMID: 25773567 Free article. Review.

4

Family Spillover Effects in Pediatric Cost-Utility Analyses.

Lavelle TA, D'Cruz BN, Mohit B, Ungar WJ, Prosser LA, Tsiplova K, Vera-Llonch M, Lin PJ. Lavelle TA, et al. Among authors: lin pj. Appl Health Econ Health Policy. 2019 Apr;17(2):163-174. doi: 10.1007/s40258-018-0436-0. Appl Health Econ Health Policy. 2019. PMID: 30350218 Review.

5

Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.

Lin PJ, D'Cruz B, Leech AA, Neumann PJ, Sanon Aigbogun M, Oberdhan D, Lavelle TA. Lin PJ, et al. Pharmacoeconomics. 2019 Apr;37(4):597-608. doi: 10.1007/s40273-019-00788-3. Pharmacoeconomics. 2019. PMID: 30903567

6

Is Value Portable? An Examination of Contextual and Practical Considerations that Affect the Transferability of Value Assessments between Settings.

Synnott PG, Lin PJ, Hickson SS, Glaetzer C, Ollendorf DA. Synnott PG, et al. Among authors: lin pj. Int J Technol Assess Health Care. 2022 Apr 21:1-26. doi: 10.1017/S026646232200023X. Online ahead of print. Int J Technol Assess Health Care. 2022. PMID: 35443906 No abstract available.

7

Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers.

Hlávka JP, Lavelle TA, Neumann PJ, Lin PJ. Hlávka JP, et al. Among authors: lin pj. Pharmacoeconomics. 2022 Jul;40(7):647-652. doi: 10.1007/s40273-022-01150-w. Epub 2022 May 13. Pharmacoeconomics. 2022. PMID: 35553029 Free PMC article.

8

When are breakthrough therapies cost-effective?

Olchanski N, Lin PJ, Yeh WS, Kowal S, Cohen JT. Olchanski N, et al. Among authors: lin pj. J Manag Care Spec Pharm. 2022 Jul;28(7):732-739. doi: 10.18553/jmcp.2022.28.7.732. J Manag Care Spec Pharm. 2022. PMID: 35737862 Free PMC article.

9

Family Spillover Effects: Are Economic Evaluations Misrepresenting the Value of Healthcare Interventions to Society?

Leech AA, Lin PJ, D'Cruz B, Parsons SK, Lavelle TA. Leech AA, et al. Among authors: lin pj. Appl Health Econ Health Policy. 2023 Jan;21(1):5-10. doi: 10.1007/s40258-022-00755-8. Epub 2022 Aug 23. Appl Health Econ Health Policy. 2023. PMID: 35997896 Free PMC article.

10

The State of Cost-Utility Analyses in Asia: A Systematic Review.

Thorat T, Lin PJ, Neumann PJ. Thorat T, et al. Among authors: lin pj. Value Health Reg Issues. 2015 May;6:7-13. doi: 10.1016/j.vhri.2015.02.001. Epub 2015 Mar 24. Value Health Reg Issues. 2015. PMID: 29698196 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

613 results

Search Page